Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis

Breast Cancer Research and Treatment

Volumn 118, Issue 1, 2009, Pages 33-43

  Li, Zengshan ^a,b   Carrier, Latonya ^a   Belame, Aditi ^a   Thiyagarajah, Arunthavarani ^c   Salvo, Virgilio A ^a   Burow, Matthew E ^a   Rowan, Brian G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c TULANE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Apoptosis; Breast cancer; Proliferation; Selenium; Synergy; Tamoxifen; Xenograft

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; METHYLSELENOCYSTEINE; PROGESTERONE RECEPTOR; SELENIUM; TAMOXIFEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CYCLIN D1; CYSTEINE; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; ORGANOSELENIUM COMPOUNDS; RANDOM ALLOCATION; RECEPTORS, PROGESTERONE; SPECIFIC PATHOGEN-FREE ORGANISMS; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349899082     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0216-x     Document Type: Article

References (31)

1. Y Dong HE Ganther C Stewart, et al. 2002 Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays Cancer Res 62 708 714 1:CAS:528:DC%2BD38Xht1Krur4%3D 11830524
2. Z Wang C Jiang J Lu 2002 Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol Mol Carcinog 34 113 120 10.1002/mc.10056 10.1002/mc.10056 1:CAS:528:DC%2BD38Xlt1Srurs%3D 12112305 (Pubitemid 34747321)
3. R Sinha D Medina 1997 Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells Carcinogenesis 18 1541 1547 10.1093/carcin/18.8.1541 10.1093/carcin/18.8.1541 1:CAS:528:DyaK2sXlsF2rt7o%3D 9276628 (Pubitemid 28134777)
4. C Ip Z Zhu HJ Thompson, et al. 1999 Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat Anticancer Res 19 2875 2880 1:CAS:528:DC%2BD3cXmvF2gtQ%3D%3D 10652567
5. C Ip 1998 Lessons from basic research in selenium and cancer prevention J Nutr 128 1845 1854 1:CAS:528:DyaK1cXntF2ksLY%3D 9808633
6. LC Clark GF Combs Jr BW Turnbull, et al. 1996 Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group JAMA 276 1957 1963 10.1001/jama.276.24.1957 10.1001/jama.276.24.1957 1:CAS:528:DyaK2sXks1eksg%3D%3D 8971064
7. S Cao FA Durrani YM Rustum 2004 Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts Clin Cancer Res 10 2561 2569 10.1158/1078-0432.CCR-03-0268 10.1158/1078-0432.CCR-03-0268 1:CAS:528:DC%2BD2cXivFSqsbc%3D 15073137 (Pubitemid 38445719)
8. C Ip Y Dong 2001 Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland Anticancer Res 21 863 867 1:CAS:528:DC%2BD3MXksVOjsLg%3D 11396176
9. J Lu C Jiang M Kaeck, et al. 1995 Dissociation of the genotoxic and growth inhibitory effects of selenium Biochem Pharmacol 50 213 219 10.1016/0006-2952(95)00119-K 10.1016/0006-2952(95)00119-K 1:CAS:528: DyaK2MXnt1Sktb4%3D 7632165
10. Y Dong H Zhang L Hawthorn, et al. 2003 Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array Cancer Res 63 52 59 1:CAS:528:DC%2BD3sXjvFKmtg%3D%3D 12517777
11. S Li Y Zhou R Wang, et al. 2007 Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates Mol Cancer Ther 6 1031 1038 10.1158/1535-7163.MCT-06-0643 10.1158/1535-7163.MCT-06-0643 1:CAS:528:DC%2BD2sXivV2nt7w%3D 17339365 (Pubitemid 46554573)
12. SO Lee J Yeon Chun N Nadiminty, et al. 2006 Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA) Prostate 66 1070 1075 10.1002/pros.20329 10.1002/pros.20329 1:CAS:528:DC%2BD28Xnt1CntLs%3D 16637076 (Pubitemid 43939210)
13. A Bhattacharya M Seshadri SD Oven, et al. 2008 Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs Clin Cancer Res 14 3926 3932 10.1158/1078-0432. CCR-08-0212 10.1158/1078-0432.CCR-08-0212 1:CAS:528:DC%2BD1cXntlWrtbo%3D 18559614
14. RR Love 1989 Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects J Clin Oncol 7 803 815 1:STN:280:DyaL1M3jsFOjtg%3D%3D 2654333
15. VC Jordan 1992 The strategic use of antiestrogens to control the development and growth of breast cancer Cancer 70 977 982 1:STN:280: DyaK38zks1Gjug%3D%3D 1638467
16. B Fisher JP Costantino DL Wickerham, et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371 1388 10.1093/jnci/90.18.1371 10.1093/jnci/90.18.1371 1:CAS:528:DyaK1cXmtlelurs%3D 9747868
17. T Fornander LE Rutqvist B Cedermark, et al. 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet 1 117 120 10.1016/S0140-6736(89)91141-0 10.1016/S0140-6736(89)91141-0 1:STN:280: DyaL1M%2Fps1WgsQ%3D%3D 2563046
18. SR Johnston M Dowsett IE Smith 1992 Towards a molecular basis for tamoxifen resistance in breast cancer Ann Oncol 3 503 511 1:STN:280: DyaK38zmtVGgtw%3D%3D 1498070
19. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 10.1056/NEJM199811263392207 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D 9828250 (Pubitemid 28536137)
20. Z Li L Carrier BG Rowan 2008 Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells Mol Cancer Ther 7 3056 3063 10.1158/1535-7163.MCT-07-2142 10.1158/1535-7163.MCT-07-2142 1:CAS:528:DC%2BD1cXhtFSmsL%2FO 18790785
21. YM Shah A Kaul Y Dong, et al. 2005 Attenuation of estrogen receptor alpha (ERalpha) signaling by selenium in breast cancer cells via downregulation of ERalpha gene expression Breast Cancer Res Treat 92 239 250 10.1007/s10549-005- 3203-5 10.1007/s10549-005-3203-5 1:CAS:528:DC%2BD2MXpvV2gsLk%3D 16155795 (Pubitemid 41279634)
22. VA Salvo SM Boue JP Fonseca, et al. 2006 Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis Clin Cancer Res 12 7159 7164 10.1158/1078-0432.CCR-06-1426 10.1158/1078-0432.CCR-06-1426 1:CAS:528:DC%2BD28Xht1Kns7bJ 17145841 (Pubitemid 44974517)
23. S Hansen DA Grabau C Rose, et al. 1998 Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density Lab Invest 78 1563 1573 1:STN:280:DyaK1M%2Fps1arsQ%3D%3D 9881956
24. YM Shah M Al Dhaheri Y Dong, et al. 2005 Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells Mol Cancer Ther 4 1239 1249 10.1158/1535-7163.MCT-05-0046 10.1158/1535-7163.MCT-05-0046 1:CAS:528:DC%2BD2MXnt1ShtLc%3D 16093440 (Pubitemid 41149572)
25. R Hui AL Cornish RA McClelland, et al. 1996 Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer Clin Cancer Res 2 923 928 1:CAS:528:DyaK28XjvVyrtLg%3D 9816251
26. B Moy PE Goss 2006 Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches Clin Cancer Res 12 4790 4793 10.1158/1078-0432.CCR-06-1535 10.1158/1078-0432.CCR-06-1535 1:CAS:528: DC%2BD28XotFKgs7k%3D 16914563 (Pubitemid 44338562)
27. Jiang C, Jiang W, Ip C et al (1999) Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 26:213-225. doi:10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0. CO;2-Z
28. C Jiang KH Kim Z Wang, et al. 2004 Methyl selenium-induced vascular endothelial apoptosis is executed by caspases and principally mediated by p38 MAPK pathway Nutr Cancer 49 174 183 10.1207/s15327914nc4902-9 10.1207/s15327914nc4902-9 1:CAS:528:DC%2BD2cXhtVentrbN 15489211
29. Z Wang H Hu G Li, et al. 2008 Methylseleninic acid inhibits microvascular endothelial cell cycle progression and decreases tumor microvessel density Int J Cancer 122 15 24 10.1002/ijc.23077 10.1002/ijc.23077 1:CAS:528: DC%2BD2sXhsVSgtb%2FN 17847021 (Pubitemid 350209973)
30. Y Rustum S Cao F Durrani, et al. 2004 Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity J Clin Oncol 22 2068 meeting abstracts
31. MG Fakih L Pendyala W Brady, et al. 2008 A phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors Cancer Chemother Pharmacol 62 499 508 10.1007/s00280-007-0631-4 10.1007/s00280-007-0631-4 1:CAS:528:DC%2BD1cXnt1Cjsro%3D 17989978